Cost, efficacy, and safety comparison between early intensive and escalating strategies for multiple sclerosis: A systematic review and meta-analysis
Leonardo Zumerkorn Pipek, João Vitor Mahler, Rafaela Farias Vidigal Nascimento, Samira Luísa Apóstolos‐Pereira, Guilherme Diogo Silva, Dagoberto Callegaro
Topics & Concepts
MedicineAlemtuzumabExpanded Disability Status ScaleNatalizumabMultiple sclerosisMeta-analysisAdverse effectMEDLINEFingolimodCost effectivenessPhysical therapyIntensive care medicinePediatricsInternal medicineTransplantationPsychiatryLawPolitical scienceRisk analysis (engineering)Multiple Sclerosis Research StudiesAmyotrophic Lateral Sclerosis ResearchPeripheral Neuropathies and Disorders